Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER in pediatric MDD
NCT03569475Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levomilnacipran in major depressive disorder (MDD), sponsored by Allergan. Started Jul 2018; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03569475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569475.